Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Illinois Wellness Insider.
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
August 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
Press releases published on July 29, 2025
Cannabix Technologies Receives Notice of Allowance from CIPO for Contactless Breath Analysis Patent Application
GlobeNewswire
·
July 29, 2025
VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) is pleased to report that the Canadian Intellectual Property Office (CIPO) has issued a …
CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
July 29, 2025
MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular …
Foundation Health to Bring AI-Powered Patient Communication to Intermountain Health’s Specialty Pharmacy Patients
GlobeNewswire
·
July 29, 2025
SAN FRANCISCO, July 29, 2025 (GLOBE NEWSWIRE) -- In a new strategic partnership, Foundation Health's PAIGE AI platform will be used to automate patient outreach and communication workflows in an initial 6-month program at Intermountain Health’s specialty …
IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025
GlobeNewswire
·
July 29, 2025
LAWRENCEVILLE, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. ET on Tuesday, …
Cedar Gate Data Finds Nearly 60% of New Mothers Miss Essential Postpartum Follow-Up Care
GlobeNewswire
·
July 29, 2025
GREENWICH, Conn., July 29, 2025 (GLOBE NEWSWIRE) -- Cedar Gate Technologies (Cedar Gate), a leading value-based care technology and services company, today announced new data revealing that a majority of new mothers are missing critical postpartum care — …
Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference
GlobeNewswire
·
July 29, 2025
SEATTLE and VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of …
Quoin Pharmaceuticals Provides Product Portfolio Update
GlobeNewswire
·
July 29, 2025
Lead Product, QRX003, Being Tested in Two Active Registrational Clinical Studies for Netherton Syndrome Across the U.S., Europe, and the Middle East. QRX003 Peeling Skin Syndrome Clinical Program Continues Following Positive Initial Data Topical Rapamycin …
Branded Legacy, Inc. Signs Letter of Intent to Acquire Bio-Legacy Evaluative Group, Advancing Innovations in Intranasal Drug Delivery
GlobeNewswire
·
July 29, 2025
MELBOURNE, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (OTC: BLEG), a diversified holdings company focused on innovative health and wellness solutions, today announced the execution of a non-binding Letter of Intent (LOI) to …
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025
GlobeNewswire
·
July 29, 2025
Conference Call and Webcast Scheduled for Thursday, August 7th, 2025, at 10:00 AM ET PRINCETON, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions …
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma
GlobeNewswire
·
July 29, 2025
SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic …
Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results
GlobeNewswire
·
July 29, 2025
BOSTON, July 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …
Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease
GlobeNewswire
·
July 29, 2025
- Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration - Trial to assess safety, PK and detect early signs of efficacy - Initial data expected in mid-2026 SACRAMENTO, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- …
Izotropic’s IzoView Breast CT Device Stands Distinct vs Existing Breast Imaging Technologies
GlobeNewswire
·
July 29, 2025
- IzoView positioned to disrupt high-growth breast imaging markets with target device price of USD $500K - IzoView to launch into projected fastest-growing imaging category with potential to displace well-established technologies - Differentiated from …
Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301
GlobeNewswire
·
July 29, 2025
KANSAS CITY, Kan., July 29, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation …
Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream
GlobeNewswire
·
July 29, 2025
A first-of-its-kind solution for women’s arousal in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 2025 Collaboration leverages Rosy Wellness’ extensive …
ProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy Statement
GlobeNewswire
·
July 29, 2025
Proxy Sets Company on a Path to Attract the Optimal Crypto Treasury Strategy Increase in Authorized Shares to 1 Billion Would Position the Company to Attract Industry-Leading Market Participants and High-Value Crypto Treasury Transactions UNIONDALE, NY, …
Exagen Inc. Reports Strong Q2 2025 Results
GlobeNewswire
·
July 29, 2025
CARLSBAD, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2025, and recent corporate updates. Three Months Ended …
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
GlobeNewswire
·
July 29, 2025
SYDNEY, AUSTRALIA, July 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the …
Vivex Biologics, Inc. Completes Subject Enrollment for its ASCEND Trial Evaluating VIA Disc NP™ for Symptomatic Disc Degeneration
GlobeNewswire
·
July 29, 2025
MIAMI, July 29, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced that it has completed subject enrollment in its ASCEND clinical trial evaluating VIA Disc NP for symptomatic …
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
GlobeNewswire
·
July 29, 2025
Presentation to highlight the Company’s proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company’s Phase 1b clinical trial design and optimization of biomarkers in AD Progress with trial …